Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial

Majem M.Goldman J.W.John T.Grohe C.Laktionov K.Kim S.-W.Kato T.Vu H.V.Lu S.Li S.Lee K.Y.Akewanlop C.CHONG-JEN YUde Marinis F.Bonanno L.Domine M.Shepherd F.A.Atagi S.Zeng L.Kulkarni D.Medic N.Tsuboi M.Herbst R.S.Wu Y.-L.2022-06-272022-06-2720221078-0432https://www.scopus.com/inward/record.uri?eid=2-s2.0-85129128231&doi=10.1158%2f1078-0432.CCR-21-3530&partnerID=40&md5=bfd5e897b9a6c6f7594ad2b17863a8b1https://scholars.lib.ntu.edu.tw/handle/123456789/613969[SDGs]SDG3Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trialjournal article10.1158/1078-0432.CCR-21-3530350129272-s2.0-85129128231